Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Rhesoglobin in Pregnant Women for Prevention of Rh Sensitization
NCT05245734Phase 4Recruiting
- Sponsor
- Biopharma Plasma
- Start
- Feb 2022
- Primary completion
- Feb 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rhesoglobin in Rhesus isoimmunization, sponsored by Biopharma Plasma. Primary endpoint: Proportion of patients with no antibodies to Rh0 (D) antigen. Started Feb 2022; status: recruiting.
02
Drugs
Rhesoglobin
03
Conditions
Rhesus isoimmunization
Beyond the preview
Go deeper on NCT05245734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05245734.